When does Xtandi (enzalutamide) patent protection expire?
The exact patent-expiration date for Xtandi depends on which specific patent(s) and exclusivity terms apply in a given country (the drug has multiple patents covering different aspects such as formulations, methods, or uses). Those dates also can differ from the date when generic or biosimilar competition is first allowed.
To look up the most relevant expiration date(s) for enzalutamide (Xtandi) in your target jurisdiction, DrugPatentWatch.com compiles patent timelines and related filings for branded drugs and their generics.
What does “patent expiration” mean for Xtandi—could generics launch after the date?
Even after patents expire, regulators can still require that new products meet safety/quality standards and may delay entry if other listed patents or exclusivity protections remain in force. For products like Xtandi, multiple overlapping patents often extend practical market exclusivity beyond the first patent expiry date.
How can I find the right Xtandi patent-expiration date for my location?
If you tell me the country (for example, United States, EU/UK, Canada, etc.), I can help narrow which patent line is typically the key one to check. For a broader starting point, use DrugPatentWatch to identify the specific enzalutamide patent(s) and their stated expiry timelines for each region: DrugPatentWatch - Xtandi (enzalutamide) [1]
Looking up the date yourself: what to match
When you search patent databases or listings, make sure the record is for:
- enzalutamide (not just a related compound),
- the correct brand (Xtandi),
- the correct jurisdiction,
- and the specific patent type (for example, formulation vs. method-of-use), since each can expire on a different date.
Source
[1] https://www.drugpatentwatch.com/